OverviewChartNewsTraderScreen

FibroGen/  US31572Q8087  /

IEX
08/11/2024  21:59:47 Chg. 0.00 Volume Bid- Ask- High Low
0.32USD +1.13% 5,072
Turnover: 1,615.81		 -Bid Size: - -Ask Size: - 0.32 0.31
GlobeNewswire 06/08 FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 30/07 FibroGen to Report Second Quarter 2024 Financial Results
GlobeNewswire 30/07 FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Pro...
GlobeNewswire 16/07 Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board
GlobeNewswire 27/06 Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 M...
GlobeNewswire 18/06 FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program ...
GlobeNewswire 13/06 Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors
GlobeNewswire 04/06 Bitterroot Bio Announces Appointment of Georgette Verdin as Chief People Officer and Sherwin Chen as...
GlobeNewswire 03/06 FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroG...
GlobeNewswire 03/06 FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 T...
GlobeNewswire 03/06 FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswire 23/05 FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) ...
GlobeNewswire 07/05 FibroGen to Participate in Upcoming Investor Conferences
GlobeNewswire 06/05 FibroGen Reports First Quarter 2024 Financial Results
GlobeNewswire 29/04 FibroGen to Report First Quarter 2024 Financial Results
GlobeNewswire 24/04 FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combinat...
GlobeNewswire 02/04 FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metast...
GlobeNewswire 26/03 FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
GlobeNewswire 11/03 FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
GlobeNewswire 26/02 FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire 26/02 FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZenec...
GlobeNewswire 20/02 FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire 05/02 FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program ...
GlobeNewswire 25/01 FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action ...
GlobeNewswire 09/12/2023 FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower ...